MXRA7 and renal carcinoma: According to The Human Protein Atlas (HPA) [10], better survival outcomes were observed for 693 renal cancer patients with lower-than-cutoff MXRA7 expression compared with 184 patients with higher MXRA7 expression (P score = 0.0054), with 5-year survival rates of 71% vs 60% in these two groups respectively (as of July 8th, 2024).